These drugs may be used to treat glioblastoma clinically in the future, such as PD-0332991, which is a selective CDK4/6 inhibitor, and presented outstanding results in phase II clinical trials of estrogen receptor- (ER-) positive HER2-negative breast cancer. This evidence concerns the gene CDK4 and glioblastoma.